Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 IsomAb Names Dr. Gary Burgess as Chief Medical Officer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

IsomAb Names Dr. Gary Burgess as Chief Medical Officer

Burgess has 20+ years of experience across all phases of drug development in a broad range of disease and therapeutic areas.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

IsomAb Ltd, a UK-based biotechnology company developing novel isoform-specific disease modifying antibody treatments, for peripheral arterial disease and other ischaemic conditions, has appointed Dr. Gary Burgess as Chief Medical Officer (CMO).

Burgess has over two decades of experience spanning all phases of drug development, from Phase 1 to Phase 4, in a diverse range of diseases and therapeutic areas. Throughout this journey, he has maintained close collaboration with regulatory agencies, including the FDA, EMA, and PMDA.

Having held senior positions at Pfizer, Aerami Therapeutics, Vectura Ltd and Conatus Pharmaceuticals, Burgess has gained recognition as an international expert in Metabolic Associated Steatohepatitis (MASH, formerly NASH) and pulmonary hypertension. Whilst at Pfizer he also worked in the Cardiovascular Therapeutic Area on treatments for vascular diseases. 

Burgess completed his undergraduate and postgraduate medical training at the University of Stellenbosch.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics